The loss of Capricor Therapeutics under GAAP for 9 months of 2020 was $9.479 million, up 53.6% from $6.172 million in the previous year. Revenue decreased 3.1 times to $252.42 thousand, against $782.928 thousand in the previous year.
The loss of Capricor Therapeutics under GAAP for 9 months of 2020 was $9.479 million, up 53.6% from $6.172 million in the previous year. Revenue decreased 3.1 times to $252.42 thousand, against $782.928 thousand in the previous year. 
irdirect.net
English (US) 